Michail Vikelis and Andreas A. Argyriou contributed equally to this work.
Evidence on whether the therapeutic effect and good safety profile of onabotulinumtoxinA (Botox®) in chronic migraine (CM) patients is maintained over long term treatment is still limited. We herein aimed at assessing whether there is a sustained benefit and good safety with repeated onabotulinumtoxinA sessions in CM over more than three years of treatment.
We prospectively enrolled 65 CM patients, who were classified as responders after three sessions of onabotulinumtoxinA and were eligible to further continue treatment. Data documenting longitudinal changes from the trimester after the third onabotulinumtoxinA administration (T1) to the trimester after completing two years of treatment (T2) and eventually to the trimester after completing three years of treatment (T3) in (i) mean number of monthly headache days (ii) migraine severity as expressed by the mean number of days with peak headache intensity of > 4/10, and (iii) mean number of days with use of any acute headache medication, were prospectively collected from patients’ headache diaries.
A total of 56 (86.1%) of 65 patients achieved to attain onabotulinumtoxinA over three years. At T3, a significant reduction in mean monthly headache days was evident, compared to T1 (3.4 ± 1.7 vs 7.2 ± 3.8; P < 0.001) with diminished mean number of monthly days with peak headache intensity of more than 4/10 and a significant change in days using acute headache medications per month between T1 and T3 (2.8 ± 1.3 vs 4.7 ± 3.2; P < 0.001). Significant changes were also noticed in all efficacy variables from T2 to T3. Therapy was safe and well tolerated with low rates of adverse events or drop-outs.
The long -term treatment with onabotulinumtoxinA proved effective, safe and well tolerated over three years. Our findings support the strategy to consistently deliver sessions of use of onabotulinumtoxinΑ over long time in CM patients (Trial registration NTC03606356, registered retrospectively, 28 July 2018).
Headache Classification Committee of the International Headache Society (IHS) (2018) The international classification of headache disorders, 3rd edition. Cephalalgia 38(1):1–211 CrossRef
Barbanti P, Egeo G, Fofi L, Aurilia C, Piroso S (2015) Rationale for use of onabotulinum toxin a (BOTOX) in chronic migraine. Neurol Sci 36(Suppl 1):29–32 CrossRef
Aurora SK, Dodick DW, Turkel CC, RE DG, Silberstein SD, Lipton RB, Diener HC, Brin MF, PREEMPT 1 Chronic Migraine Study Group (2010) Onabotulinumtoxin a for treatment of chronic migraine: results from the double-blind, randomized placebo controlled phase of the PREEMPT 1 trial. Cephalalgia 30:793–803 CrossRef
Diener HC, Dodick DW, Aurora SK, Turkel CC, RE DG, Lipton RB, Silberstein SD, Brin MF, PREEMPT 2 Chronic Migraine Study Group (2010) Onabotulinumtoxin a for treatment of chronic migraine: results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial. Cephalalgia 30:804–814 CrossRef
Frampton JE, Silberstein S Onabotulinumtoxin a (2018) a review in the prevention of chronic migraine. Drugs 78:589–600 CrossRef
Silberstein SD, Dodick DW, Aurora SK, Diener HC, DeGryse RE, Lipton RB, Turkel CC (2015) Per cent of patients with chronic migraine who responded per Onabotulinumtoxin a treatment cycle: PREEMPT. J Neurol Neurosurg Psychiatry 86:996–1001 CrossRef
Cernuda-Morollón E, Ramón C, Larrosa D, Alvarez R, Riesco N, Pascual J (2015) Long-term experience with Onabotulinumtoxin a in the treatment of chronic migraine: what happens after one year? Cephalalgia 35:864–868 CrossRef
Negro A, Curto M, Lionetto L, Martelletti P (2015) A two years open-label prospective study of Onabotulinumtoxin a 195 U in medication overuse headache: a real-world experience. J Headache Pain 17(1)
Blumenfeld AM, Stark RJ, Freeman MC, Orejudos A, Manack Adams A (2018) Long-term study of the efficacy and safety of Onabotulinumtoxin a for the prevention of chronic migraine: COMPEL study. J Headache Pain 19:13 CrossRef
Farinelli I, Coloprisco G, De Filippis S, Martelletti P (2006) Long-term benefits of botulinum toxin type a (BOTOX) in chronic daily headache: a five-year long experience. J Headache Pain 7:407–412 CrossRef
Guerzoni S, Pellesi L, Baraldi C, Cainazzo MM, Negro A, Martelletti P, Pini LA (2017) Long-term treatment benefits and prolonged efficacy of Onabotulinumtoxin a in patients affected by chronic migraine and medication overuse headache over 3 years of therapy. Front Neurol 8:586 CrossRef
Negro A, Curto M, Lionetto L, Giamberardino MA, Martelletti P (2016) Chronic migraine treatment: from Onabotulinumtoxin a onwards. Expert Rev Neurother 16:1217–1227 CrossRef
Vikelis M, Argyriou AA, Dermitzakis EV, Spingos KC, Mitsikostas DD (2016) Onabotulinumtoxin a treatment in Greek patients with chronic migraine. J Headache Pain 17:84 CrossRef
Chiang CC, Starling AJ (2017) Onabotulinumtoxin a in the treatment of patients with chronic migraine: clinical evidence and experience. Ther Adv Neurol Disord 10:397–406 CrossRef
Lipton RB (2015) Risk factors for and Management of Medication-Overuse Headache. Continuum (Minneap Minn) 21:1118–1131
Vikelis Μ, Spingos KC, Rapoport AM (2018) A new era in headache treatment. Neurol Sci 39(Suppl 1):S47–S58 CrossRef
Guerzoni S, Pellesi L, Baraldi C, Pini LA (2015) Increased efficacy of regularly repeated cycles with Onabotulinumtoxin a in MOH patients beyond the first year of treatment. J Headache Pain 17:48 CrossRef
Weatherall MW (2015) The diagnosis and treatment of chronic migraine. Ther Adv Chronic Dis 6(3):115–123 CrossRef
Tassorelli C, Tedeschi G, Sarchielli P, Pini LA, Grazzi L, Geppetti P, De Tommaso M, Aguggia M, Cortelli P, Martelletti P (2018) Optimizing the long-term management of chronic migraine with onabotulinumtoxinA in real life. Expert Rev Neurother 18(2):167–176 CrossRef
Mathew NT (2011) Pathophysiology of chronic migraine and mode of action of preventive medications. Headache 51 Suppl 2:84–92 CrossRef
Aicua-Rapun I, Martínez-Velasco E, Rojo A, Hernando A, Ruiz M, Carreres A, Porqueres E, Herrero S, Iglesias F, Guerrero AL (2016) Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin a during more than one year. J Headache Pain 17:112 CrossRef
D' Amico D, Tepper SJ (2008) Prophylaxis of migraine: general principles and patient acceptance. Neuropsychiatr Dis Treat 4:1155–1167 CrossRef
Davies B, Gaul C, Martelletti P, García-Moncó JC (2017 Sep 6) Brown S (2017) real-life use of onabotulinumtoxinA for symptom relief in patients with chronic migraine: REPOSE study methodology and baseline data. J Headache Pain 18(1):93 CrossRef
- Sustained onabotulinumtoxinA therapeutic benefits in patients with chronic migraine over 3 years of treatment
Andreas A. Argyriou
Emmanouil V. Dermitzakis
Konstantinos C. Spingos
- Springer Milan
Neu im Fachgebiet AINS
Meistgelesene Bücher aus dem Fachgebiet AINS
Mail Icon II